sunitynib adamed 25 mg kapsułki twarde
adamed pharma s.a. - sunitynibu jabłaczan - kapsułki twarde - 25 mg
sunitynib adamed 12,5 mg kapsułki twarde
adamed pharma s.a. - sunitynibu jabłaczan - kapsułki twarde - 12,5 mg
sunitinib msn 50 mg kapsułki twarde
msn labs europe limited - sunitinibum - kapsułki twarde - 50 mg
sunitinib msn 37,5 mg kapsułki twarde
msn labs europe limited - sunitinibum - kapsułki twarde - 37,5 mg
sunitinib msn 25 mg kapsułki twarde
msn labs europe limited - sunitinibum - kapsułki twarde - 25 mg
sunitinib msn 12,5 mg kapsułki twarde
msn labs europe limited - sunitinibum - kapsułki twarde - 12,5 mg
sunitinib synthon 25 mg kapsułki twarde
synthon b.v. - sunitynibu jabłaczan - kapsułki twarde - 25 mg
sunitinib synthon 12,5 mg kapsułki twarde
synthon b.v. - sunitynibu jabłaczan - kapsułki twarde - 12,5 mg
sunitinib synthon 50 mg kapsułki twarde
synthon b.v. - sunitynibu jabłaczan - kapsułki twarde - 50 mg
tagrisso
astrazeneca ab - osimertinib mesilate - rak, niedrobnokomórkowe płuca - inne leki przeciwnowotworowe, inhibitory białka kinazy - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.